A new treatment option for adult and paediatric patients with a rare soft tissue cancer has been approved. The FDA has approved new immunotherapy drug atezolizumab (Tecentriq) for patients with advanced alveolar soft part sarcoma (ASPS) that has either spread to other parts of the body or cannot be removed by surgery for another reason.
Ook interessant voor je
NICE recommends Pfizer’s rimegepant for preventing episodic migraine attacks
NICE recommends Pfizer’s rimegepant for preventing episodic migraine attacks The National Institute for Care and Excellence (NICE) has announced that it has recommended an oral treatment for the prevention of episodic...
1 x gelezen
Five things for pharma marketers to know: Friday, June 2, 2023
Five things for pharma marketers to know: The Centers for Medicare and Medicaid Services announced plans to broadly cover a new class of Alzheimer’s drugs pending approval by the Food and Drug Administration. ...
2 x gelezen
Five things for pharma marketers to know: Thursday, June 1, 2023
Five things for pharma marketers to know RA Capital-backed Summation Bio is “terminating operations” next month, per an employee’s LinkedIn profile update. Abbott sued a former scientist over alleged trade-secret theft...
4 x gelezen